文献速递消化、代谢与肾脏急症

曲马多与可待因处方调配与死亡率及其他不良临床结局的关联

Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes.
PubMed 文献 · JAMA · 2021-01-01
一句话结论门诊新处方曲马多较可待因与1年内全因死亡、心血管事件和骨折风险显著升高相关,需谨慎解读。

与可待因相比,曲马多调配与更高的全因死亡风险(HR 2.31, 95%CI 2.08-2.56;ARD 7.37/1000人年)、心血管事件(HR 1.15, 95%CI 1.05-1.27;ARD 1.36/1000人年)和骨折(HR 1.50, 95%CI 1.37-1.65;ARD 4.10/1000人年)显著相关;跌倒、谵妄、便秘、阿片滥用/依赖或睡眠障碍风险无显著差异。鉴于潜在残余混杂,结果需谨慎解读。

要点

  • 在门诊成人中,新处方曲马多较可待因与1年内全因死亡风险升高相关(HR 2.31, 95%CI 2.08-2.56;ARD 7.37/1000人年)。
  • 曲马多较可待因与心血管事件风险升高相关(HR 1.15, 95%CI 1.05-1.27;ARD 1.36/1000人年)。
  • 曲马多较可待因与骨折风险升高相关(HR 1.50, 95%CI 1.37-1.65;ARD 4.10/1000人年)。
  • 跌倒、谵妄、便秘、阿片滥用/依赖或睡眠障碍风险在两组间无显著差异。
  • 结果为观察性关联,存在残余混杂可能,需谨慎解读,不能直接推断因果关系。

适用人群与场景

  • 排除:原文未提及具体排除标准。
  • 场景:门诊(初级保健)处方调配,非急诊/ICU住院场景。

诊断标准与关键阈值

  • 暴露定义:新处方调配曲马多或可待因,即既往1年内无该药调配记录。
  • 结局评估:首次调配后1年内的全因死亡、心血管事件、骨折、便秘、谵妄、跌倒、阿片滥用/依赖和睡眠障碍。

处置流程与药物剂量

  • 原文未提及具体处置流程或药物剂量方案。

红旗征与不能漏的情况

  • 原文未提及需立即处理或不能漏诊的红旗征。

研究设计与关键结果

  • 主要终点:与可待因相比,曲马多调配与更高的全因死亡风险相关(发生率13.00 vs 5.61/1000人年;HR 2.31, 95%CI 2.08-2.56;ARD 7.37, 95%CI 6.09-8.78/1000人年)。
  • 关键次要终点:心血管事件(HR 1.15, 95%CI 1.05-1.27;ARD 1.36, 95%CI 0.45-2.36/1000人年)和骨折(HR 1.50, 95%CI 1.37-1.65;ARD 4.10, 95%CI 3.02-5.29/1000人年)风险显著升高。
  • 其他终点:跌倒、谵妄、便秘、阿片滥用/依赖或睡眠障碍风险无显著差异。
  • 不良事件:原文未单独报告不良事件,上述结局即为研究终点。

证据类型、等级与局限

  • 证据类型:回顾性、基于人群的倾向评分匹配队列研究(观察性研究),非RCT。
  • 证据等级/推荐强度:原文未提及正式证据等级或推荐强度。
  • 局限:观察性设计存在潜在残余混杂(原文明确提及),结果需谨慎解读;其他局限(如单中心、回顾性、开放标签等)原文未具体说明,但设计本身为回顾性数据库研究。

对床旁实践的改变

  • 在门诊成人慢性非癌痛患者中,选择曲马多而非可待因时需权衡较高的全因死亡、心血管事件和骨折风险(基于观察性关联,非因果结论)。
  • 该研究不适用于急诊/ICU急性疼痛管理决策,因人群为门诊初级保健患者,结局为1年内长期风险。
  • 常见陷阱:将观察性关联误读为因果关系;本研究未提供急诊/ICU场景的剂量或监测建议。

指南或共识出处

  • 原文未提及指南或共识名称;来源为JAMA发表的原始研究。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Although tramadol is increasingly used to manage chronic noncancer pain, few safety studies have compared it with other opioids.

OBJECTIVE: To assess the associations of tramadol, compared with codeine, with mortality and other adverse clinical outcomes as used in outpatient settings.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective, population-based, propensity score-matched cohort study using a primary care database with routinely collected medical records and pharmacy dispensations covering more than 80% of the population of Catalonia, Spain (≈6 million people). Patients 18 years or older with 1 or more year of available data and dispensation of tramadol or codeine (2007-2017) were included and followed up to December 31, 2017.

EXPOSURES: New prescription dispensation of tramadol or codeine (no dispensation in the previous year).

MAIN OUTCOMES AND MEASURES: Outcomes studied were all-cause mortality, cardiovascular events, fractures, constipation, delirium, falls, opioid abuse/dependence, and sleep disorders within 1 year after the first dispensation. Absolute rate differences (ARDs) and hazard ratios (HRs) with 95% confidence intervals were calculated using cause-specific Cox models.

RESULTS: Of the 1 093 064 patients with a tramadol or codeine dispensation during the study period (326 921 for tramadol, 762 492 for codeine, 3651 for both drugs concomitantly), a total of 368 960 patients (184 480 propensity score-matched pairs) were included after study exclusions and propensity score matching (mean age, 53.1 [SD, 16.1] years; 57.3% women). Compared with codeine, tramadol dispensation was significantly associated with a higher risk of all-cause mortality (incidence, 13.00 vs 5.61 per 1000 person-years; HR, 2.31 [95% CI, 2.08-2.56]; ARD, 7.37 [95% CI, 6.09-8.78] per 1000 person-years), cardiovascular events (incidence, 10.03 vs 8.67 per 1000 person-years; HR, 1.15 [95% CI, 1.05-1.27]; ARD, 1.36 [95% CI, 0.45-2.36] per 1000 person-years), and fractures (incidence, 12.26 vs 8.13 per 1000 person-years; HR, 1.50 [95% CI, 1.37-1.65]; ARD, 4.10 [95% CI, 3.02-5.29] per 1000 person-years). No significant difference was observed for the risk of falls, delirium, constipation, opioid abuse/dependence, or sleep disorders.

CONCLUSIONS AND RELEVANCE: In this population-based cohort study, a new prescription dispensation of tramadol, compared with codeine, was significantly associated with a higher risk of subsequent all-cause mortality, cardiovascular events, and fractures, but there was no significant difference in the risk of constipation, delirium, falls, opioid abuse/dependence, or sleep disorders. The findings should be interpreted cautiously, given the potential for residual confounding.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Xie J, Strauss VY, Martinez-Laguna D, et al. Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. JAMA. 2021. PMID: 34665205. doi:10.1001/jama.2021.15255

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。